Followers | 507 |
Posts | 10138 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Sunday, August 30, 2015 10:10:46 AM
bullish
close > 1 and average volume > 100k
bullish divergence breakout
double bottom
Theravance Biopharma, Inc.
Ugland House
South Church Street
George Town, KY1-1104
Cayman Islands
Phone: 650-808-6000
Website: http://www.theravance.com
Investors: http://investor.theravance.com/index.cfm
Theravance Biopharma, Inc. engages in the research and development activities focusing on the diseases of the lung and gastrointestinal tract, and infectious diseases, as well as on the acute care setting markets. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. The company's TD-4208, an investigational long-acting muscarinic antagonist, which has completed Phase IIb study for the treatment of chronic obstructive pulmonary disease; and Axelopran, an investigational, once-daily, and oral peripherally active mu opioid receptor antagonist that is in Phase II clinical trial for opioid-induced constipation. It also offers Velusetrag, an oral and investigational medicine, which has completed first Phase II study for gastrointestinal motility disorders. The company focuses on various drug development programs, including the combination of fluticasone furoate, umeclidinium, and vilanterol; the MABA program, as monotherapy; and in combination with other therapeutically active components, such as an inhaled corticosteroid. Theravance Biopharma, Inc. is incorporated in 2013 and is based in George Town, the Cayman Islands.
## source: finance.yahoo.com
Fri, 28 Aug 2015 20:40:14 GMT ~ THERAVANCE BIOPHARMA, INC. Files SEC form 8-K/A, Results of Operations and Financial Condition, Financial Statements
read full: http://biz.yahoo.com/e/150828/tbph8-k_a.html
*********************************************************
Thu, 27 Aug 2015 20:54:01 GMT ~ Theravance Biopharma to Present at the Baird 2015 Healthcare Conference
[at noodls] - August 27, 2015 DUBLIN, IRELAND -- (Marketwired) -- 08/27/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that Rick E Winningham, Chairman and Chief Executive Officer and other members ...
read full: http://www.noodls.com/view/609191CD7421533E3C9DB7BBB33B028E6B0488CC
*********************************************************
Thu, 27 Aug 2015 20:30:00 GMT ~ Theravance Biopharma to Present at the Baird 2015 Healthcare Conference
[Marketwired] - Theravance Biopharma, Inc. announced today that Rick E Winningham, Chairman and Chief Executive Officer and other members of the management team will participate in a fireside chat at the Baird 2015 Healthcare ...
read full: http://finance.yahoo.com/news/theravance-biopharma-present-baird-2015-203000731.html
*********************************************************
Thu, 27 Aug 2015 17:04:19 GMT ~ THERAVANCE BIOPHARMA, INC. Financials
read full: http://finance.yahoo.com/q/is?s=tbph
*********************************************************
Wed, 19 Aug 2015 12:37:12 GMT ~ Theravance Biopharma (TBPH) in Focus: Stock Rises 5.9%
read full: http://finance.yahoo.com/news/theravance-biopharma-tbph-focus-stock-123712233.html
*********************************************************
$TBPH charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$TBPH company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/TBPH/company-info
Ticker: $TBPH
OTC Market Place: Not Available
CIK code: not found
Company name: Theravance Biopharma, Inc.
Incorporated In:
$TBPH share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$TBPH extra dd links
Company name: Theravance Biopharma, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=TBPH+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=TBPH+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=TBPH+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/TBPH/news - http://finance.yahoo.com/q/h?s=TBPH+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/TBPH/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/TBPH/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=TBPH+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/TBPH
DTCC (dtcc.com): http://search2.dtcc.com/?q=Theravance+Biopharma%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Theravance+Biopharma%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Theravance+Biopharma%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/TBPH
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/TBPH/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/TBPH/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=TBPH&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=TBPH
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/TBPH/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=TBPH+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=TBPH+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=TBPH
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=TBPH
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=TBPH+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/TBPH/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=TBPH+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/TBPH.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=TBPH
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/TBPH/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/TBPH/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/TBPH
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/TBPH
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/TBPH:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=TBPH
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=TBPH
$TBPH DD Notes ~ http://www.ddnotesmaker.com/TBPH
Recent TBPH News
- Theravance Biopharma to Report First Quarter 2024 Financial Results on May 13, 2024 • PR Newswire (US) • 04/29/2024 10:00:00 AM
- Theravance Biopharma, Inc. to Host Virtual Key Opinion Leader (KOL) Event to Discuss Ampreloxetine's Potential for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension (nOH) in Patients with Multiple System Atrophy (MSA) on May 23, 2024 • PR Newswire (US) • 04/10/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 09:16:00 PM
- Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • PR Newswire (US) • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:11:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:10:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:08:01 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:06:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/23/2024 01:04:32 AM
- Theravance Biopharma to Participate in an Upcoming Investor Conference • PR Newswire (US) • 02/22/2024 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:12:31 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:00:32 PM
- Theravance Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024 • PR Newswire (US) • 02/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 11:16:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 11:07:26 AM
- Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) • PR Newswire (US) • 01/05/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 11:01:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 11:09:03 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2023 11:06:25 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/21/2023 10:10:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:06:39 PM
- Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors • PR Newswire (US) • 12/21/2023 10:00:00 PM
- Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 42nd Annual Healthcare Conference • PR Newswire (US) • 12/18/2023 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 11:14:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/22/2023 11:11:55 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM